Diabetes Monitor - insulin glulisine (Apidra)

insulin glulisine (Apidra)

Apidra® (insulin glulisine) is approved in both Europe and the USA. It is a synthetic rapid-lasting insulin product.

Brand name: Apidra®
Class: insulin analog
For: insulin-treated diabetes adults, and for use in insulin pumps
Route of Administration: subcutaneous
Action: short-acting insulin
Manufacturer: sanofi-aventis
Status: available in USA and some other countries
Other drugs with approximately the same duration of action: Insulin lispro (Humalog®), Insulin aspart (Novolog®).

Apidra from sanofi-aventis.

Search the DiabetesMonitor for more information about

[Top]

Webpage updated at the DiabetesMonitor 12Mar2006